Announcement of Partnership Between Orbis Medicines and Vivtex
Orbis Medicines has officially partnered with Vivtex to make significant strides in the field of oral biologic therapies. Known for its pioneering work in oral macrocycle drug discovery, Orbis is looking to utilize Vivtex’s innovative GI-ORIS™ platform. This collaboration aims to improve the screening process for gut permeability and enhance the oral bioavailability of ***nCycles***, Orbis's newest macrocycle drug breakthroughs.
The Intent Behind the Partnership
Simon Feldbæk, Managing Director and Chief Development Officer at Orbis, stated, "This collaboration broadens our ability to design for oral bioavailability during essential preclinical development phases. The resources provided by Vivtex’s validated ex vivo porcine gut model significantly enhance our understanding of how drugs interact within the human gut." This strategic alliance is focused on expediting the development of top-tier drug candidates, readying them for clinical trials.
Spotlight on the nCycles Platform
With this partnership now established, both companies will undertake extensive permeability screenings of Orbis' ***nCycles***. These macrocycles are expertly designed using Orbis’s proprietary "nGen" platform, addressing the long-standing hurdles of oral bioavailability and membrane permeability. The goal is to provide effective oral alternatives for a variety of popular biologics.
Vivtex’s Contribution to Drug Delivery Innovation
Vivtex's acclaimed GI-ORIS™ platform is a crucial element of this partnership. It enables researchers to automate the screening process in a way that effectively replicates the complexities of the gastrointestinal tract, allowing for the evaluation of numerous samples in just one day. This groundbreaking technology could dramatically cut down the time and resources typically needed for such studies, thereby speeding up the timeline for new therapies’ development.
Overview of Orbis Medicines
Orbis Medicines is leading a transformative approach to oral macrocycle drug discovery. Leveraging the advantageous properties of macrocycles and the capabilities of the ***nGen*** platform, the company is positioned to explore vast chemical spaces while delivering promising drug candidates. Orbis is dedicated to creating high-value oral alternatives to current biologic therapies, reflecting the vision set forth by its founding entity, Novo Holdings.
Details About the nGen Platform
The ***nGen*** platform serves as a revolutionary resource for generating oral macrocycle candidates, also referred to as ***nCycles***. By utilizing an extensive library of over 100 billion compounds, Orbis employs advanced automation and machine learning to swiftly advance drug candidates. The data produced through this innovative approach not only speeds up the development timeline but also improves the quality of the candidates selected for further research.
The Mission of Vivtex Corporation
Founded by researchers from prestigious academic institutions, Vivtex aims to change how biologic therapies are developed. By focusing on converting injectable biologics into oral versions, Vivtex seeks to widen patient access to beneficial treatments. Highlighting the significance of its proprietary GI-ORIS™ platform, Vivtex is committed to delivering reliable solutions for effective oral biologics.
Enhancing Biologic Therapies
Vivtex is committed to transforming the market for biologic therapies by pioneering the creation of oral biologics that could greatly improve patient compliance and treatment outcomes. Their established collaborations with various biotechnology and pharmaceutical companies further strengthen their innovative strategy, emphasizing the importance of teamwork in advancing therapeutic research.
Frequently Asked Questions
What is the main goal of the Orbis and Vivtex collaboration?
The main goal is to enhance the development of oral biologic therapies using Vivtex’s GI-ORIS™ platform for gut permeability screening, optimizing the bioavailability of Orbis’ ***nCycles***.
What are ***nCycles***?
***nCycles*** are next-generation macrocycle drug candidates being developed by Orbis Medicines, designed to be orally bioavailable and membrane permeable, addressing historical challenges in drug design.
How does the GI-ORIS™ platform work?
The GI-ORIS™ platform automates the screening process, capturing the GI tract's complexity in a microwell plate format, allowing for rapid testing of thousands of drug samples.
What therapeutic areas does Orbis target?
Orbis targets high-value oral alternatives to established biologics, aiming to offer effective treatments for numerous medical conditions that currently require injectable therapies.
Who founded Orbis Medicines?
Orbis Medicines was founded by Novo Holdings, reflecting its commitment to pioneering advancements in oral macrocycle drug discovery.
